North America Cardiac Stents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Cardiac Stents Market Size

• The North America Cardiac Stents Market size was valued at USD 2.78 billion in 2024 and is expected to reach USD 5.78  billion by 2032, at a CAGR of 12.0 % during the forecast period
• Growth in this market is attributed to rising prevalence of cardiovascular diseases, increasing preference for minimally invasive procedures, and advancements in stent technology.

Cardiac Stents Market Analysis

• Cardiac stents are small mesh tubes inserted into narrowed or blocked coronary arteries to improve blood flow and prevent heart attacks, commonly used in angioplasty.
• The market is witnessing growth due to the rising geriatric population, poor lifestyle habits, and an increase in coronary artery disease cases across North America.
• The U.S. holds the largest market share due to favorable reimbursement policies, technological innovations, and a high number of PCI (percutaneous coronary intervention) procedures.
• Canada is showing steady growth with investments in cardiac care infrastructure and rising healthcare awareness. Drug-eluting stents dominate the market due to lower restenosis rates and better long-term outcomes compared to bare-metal stents.

Report Scope and Cardiac Stents Market Segmentation      

Cardiac Stents Market Trends

“Technological Advancements in Stent Coatings and Materials”

• Cardiovascular diseases are the leading cause of death in North America, largely driven by sedentary lifestyles, obesity, hypertension, and diabetes
• As coronary artery disease continues to rise, so does the demand for effective interventions like stents
• A growing aging population further contributes to increased incidence and procedural volumes

For instance,

• Cardiovascular diseases, driven by sedentary lifestyles, obesity, and diabetes, are the leading cause of death in North America. With nearly 805,000 Americans experiencing heart attacks annually, the demand for interventional solutions like stents is rapidly growing, further fueled by an aging population and increasing coronary artery disease cases. 
• Increased public awareness and routine cardiovascular screening are further fueling the early diagnosis and treatment, supporting market growth

Cardiac Stents Market Dynamics

Driver

“Rising Prevalence of Coronary Artery Disease and Lifestyle Disorders”

• Cardiovascular diseases are the leading cause of death in North America, largely driven by sedentary lifestyles, obesity, hypertension, and diabetes
• As coronary artery disease continues to rise, so does the demand for effective interventions like stents
• A growing aging population further contributes to increased incidence and procedural volumes

For instance,

• Cardiovascular diseases, driven by sedentary lifestyles, obesity, and hypertension, are the leading cause of death in North America. With 805,000 heart attacks annually, demand for stents and interventional solutions is rising. Increased public awareness and routine screening are also supporting early diagnosis and treatment, fueling market growth.
• Increased public awareness and routine cardiovascular screening are further fueling the early diagnosis and treatment, supporting market growth

Opportunity

“Emergence of Bioabsorbable Stents to Replace Traditional Implants”

• Bioabsorbable stents represent a paradigm shift, offering temporary scaffolding without long-term foreign body presence
• These stents dissolve after healing, reducing risks associated with permanent metal implants such as inflammation or thrombosis
• Market players are investing in R&D to enhance radial strength, degradation rates, and drug-delivery mechanisms

For instance,

• By 2030, biologics are expected to comprise over 30% of pharmaceutical sales, driving demand for Cardiac Stents that ensure sterility, dosing accuracy, and ease of use. Their compatibility with injectable biologics makes them vital for delivering high-value therapies in areas like oncology, immunology, and chronic disease management.
• Such advancements may help address safety concerns and improve outcomes, especially in younger and active patients

Restraint/Challenge

“High Cost and Regulatory Hurdles Slowing Market Penetration”

• Despite technological advances, cardiac stents remain expensive, with costs ranging from several hundred to thousands of dollars depending on the type
• Reimbursement issues and pricing pressures further affect market accessibility, particularly in middle-income settings
• Moreover, regulatory approvals for new-generation stents require robust clinical evidence, delaying product launches

For instance,

• Cardiac Stents, while convenient, face safety issues such as contamination, glass breakage, and material incompatibility—especially with biologics. Recalls due to such defects raise concerns for manufacturers. Ensuring consistent quality, integrity, and regulatory compliance adds complexity and costs, potentially impacting product reliability, patient safety, and overall market confidence.
• These financial and regulatory complexities pose challenges for both established and emerging players in the North American market.

Cardiac Stents Market Scope

The market is segmented on the basis of material, design, type, application, end user, and distribution channel.

In 2025, the Drug-Eluting Stents segment is projected to dominate the market with the largest share in product type segment

Drug-eluting stents (DES) are anticipated to lead the North America cardiac stents market with over 60% share in 2025. Their superior efficacy, reduced restenosis rates, and long-term safety compared to bare-metal stents drive this dominance. Increasing preference for DES in percutaneous coronary interventions supports sustained growth and widespread adoption across clinical practices.

The Metallic Stents segment is expected to account for the largest share during the forecast period in material segment

In 2025, metallic stents, particularly cobalt-chromium and platinum-chromium types, will dominate due to their excellent radial strength and clinical success. These stents are preferred in high-pressure environments, including complex lesions. Continued innovation in alloy composition and surface coatings further enhances their market position.

Cardiac Stents Market Regional Analysis

“U.S  Holds the Largest Share in the Cardiac Stents Market”

• The U.S. dominates the cardiac stents market in North America due to advanced healthcare systems, high interventional cardiology procedure volumes, and strong regulatory frameworks
• Leading companies are headquartered in the U.S., contributing to continuous innovation, product launches, and market maturity
• Favorable reimbursement policies, growing prevalence of cardiovascular risk factors, and increased focus on patient-centric care support robust market expansion
• Public-private initiatives for heart health awareness and improved diagnostic networks further accelerate market development

“Canada is Projected to Register the Highest CAGR in the Cardiac Stents Market”

• Canada is witnessing steady growth due to investments in cardiac care, government coverage of essential interventions, and focus on value-based care
• Mexico is progressing with increased public-private collaborations to improve access to interventional cardiology
• The entry of international stent manufacturers and localized manufacturing efforts are boosting competitiveness and affordability in these countries

Cardiac Stents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Abbott Laboratories (U.S.)
•  Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Terumo Corporation (Japan)
• BIOTRONIK (Germany)
• MicroPort Scientific Corporation (China)
• B. Braun Melsungen AG (Germany)
• Biosensors International Group (Singapore)
• Cook Medical (U.S.)
• Stentys S.A. (France)
• Meril Life Sciences (India)

Latest Developments in North America Cardiac Stents Market

• In March 2025, Abbott announced successful U.S. trials for a next-generation bioabsorbable stent system with improved scaffold design and enhanced drug-elution profile
• In January 2025, Boston Scientific received FDA approval for its Synergy XD DES, an enhanced version with better flexibility and precision placement in tortuous vessel
•  In October 2024, Medtronic launched a cobalt-chromium DES in Canada with a novel antiproliferative agent aimed at reducing late-stage thrombosis and improving long-term patency

SKU-1426